Orionis Biosciences is a genome-scale drug-discovery and development company using innovative technologies for cancer and other diseases. To facilitate selective engagement with high value disease targets, Orionis is using both molecular proximity and cooperativity mechanisms with emphasis on molecular glues and cytokine immunotherapies. Molecular glues are small molecules that can influence the interactions of disease target proteins such as to promote degradation. Orionis is also designing and engineering cytokines to modulate various types of immune cells as therapeutic approaches. Orionis lead candidate in clinical trials, ORB-011, is designed to activate immune cells involved in presenting tumor antigens.

Orionis Biosciences

Founded: 2015
Location: Waltham, MA
Employee range: 1-50
Clinical stage: Clin1
Therapy area: Advanced Solid Tumors
Drug types: ONC
Lead product: ORB-011
Funding: 10-100M

Drug notes:

About:

Jobs: